Publication number: 20220362239
Abstract: A pharmaceutical composition for treating acute respiratory distress syndrome (ARDS), multiple end organ failure and survival in serious and life-threatening condition in patients with coronavirus disease 2019 (COVID-19) including (a) centhaquine; (b) antiviral therapies for SARS-CoV-2 infection (remdesivir, ivermectin, chloroquine, hydroxychloroquine, azythromicyn, tenofovir, emtricitabine, ritonavir, lopinavir, ASC09, favipiravir, danoprevir, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), recombinant human angotensin-converting enzyme 2 (rhACE2), xiyanping, alpha-interferon, fludase (DAS181), eicosapentaenoic acid free fatty acid (EPA-FFA), nitric oxide, PUL-042, Pam2CSK4 acetate, agonists of TLR2 TLR6, and TLR9), convalescent plasma, stem cells or their exosomes, immunomodulation and cytokine-targeted therapies (itolizumab, tocilizumab, sarilumab, acalabrutinib, piclidenoson, tradipitant, CD24Fc, emapalumab, anakinra, TJ003234, BLD-2660, blood purification systems, Sp
Type:
Application
Filed:
May 11, 2022
Publication date:
November 17, 2022
Applicant:
PHARMAZZ, INC.
Inventor:
Anil Gulati